Thomas Rohrer, Head of Antibody Drug Conjugation Project Evaluation at Lonza, has 30 years of experience in development, scale-up and manufacturing. He established process development and clinical manufacturing of ADC(s) at Cambrex Biopharma in 2004.
After Cambrex Biopharma was acquired by Lonza in 2007 Rohrer joined the Lonza Exclusive Synthesis ADC business team in Visp, Switzerland to help establish ADC manufacturing.
Prior to joining Lonza he held senior positions in biotherapeutics process development and manufacturing at Human Genome Sciences, Otsuka Pharmaceutical and the National Cancer Institute (NCI) – Frederick Cancer Research Facility. He holds a B.S. in Biochemistry and M.S. in Chemical Engineering.
Lonza is a founding sponsor of ADC Review, Journal of Antibody-drug Conjugates.